Liver Transplantation in Patients With CirrHosis and Severe Acute-on-Chronic Liver Failure: iNdications and outComEs
Key facts
- Where
- Atlanta, Aurora, Baltimore, Chicago, Cincinnati, Cleveland, Dallas, Houston, Los Angeles, Nashville, New York, Philadelphia, Salt Lake City, and Tampa, United StatesSee the 18 sites
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 80 years old?
Source: NCT04613921, who can take part
Where in United States
- Piedmont HealthcareAtlanta, United StatesContact: Lance SteinTaking people
- University of ColoradoAurora, United StatesContact: Michael KrissTaking people
- University of Maryland School of MedicineBaltimore, United StatesContact: Kirti ShettyTaking people
- Northwestern Memorial HospitalChicago, United StatesContact: Justin R BoikeNot yet recruiting
- The University of Chicago MedicineChicago, United StatesContact: Helen TeTaking people
- University of CincinnatiCincinnati, United StatesContact: Anna BoschNo longer taking part
- Cleveland ClinicCleveland, United StatesContact: Bijan EghtesadTaking people
- Baylor College of Medicine (Scott & White)Dallas, United StatesContact: Amar GuptaNot yet recruiting
- Baylor St. Luke's Medical CentreHouston, United StatesContact: Jalal PrasunTaking people
- Michael E. DeBakey VA Medical CenterHouston, United StatesContact: Rubén HernáezNot yet recruiting
- Cedars-Sinai Comprehensive Transplant CenterLos Angeles, United StatesContact: Alexander KuoTaking people
- Vanderbilt University Medical CenterNashville, United StatesContact: Manhal IzzyNot yet recruiting
- Icahn School of Medicine at Mount SinaiNew York, United StatesContact: Ghideon EzazTaking people
- Montefiore Medical CenterNew York, United StatesContact: Brett FortuneNot yet recruiting
- Weill Cornell MedicineNew York, United StatesContact: Russell RosenblattTaking people
- University of PennsylvaniaPhiladelphia, United StatesContact: Anna BoschNo longer taking part
- University Of Utah HealthSalt Lake City, United StatesContact: Juan Gallegos-OrozcoTaking people
- Tampa General HospitalTampa, United StatesContact: Nyingi KemmerNot yet recruiting
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorTrial details
- Who runs it
- European Foundation for Study of Chronic Liver Failure
- Trial code
- NCT04613921
- Record updated
- 20 October 2025
- Original description
Management of ACLF is mainly supportive. The poor outcomes lead physicians to consider liver transplantation as an option, even if controversial. In sicker recipients, LT results in immediate survival, but poor medium-term survival rates in some studies. The scarcity of deceased donors obliges to maximize LT success. Alternative strategies, as living-donor LT, should be explored. LDLT has impressive results in Eastern centers, but it is restrained in Western countries, due to potential life-threatening complications in the donor.Read full original descriptionShow less
Liver Transplantation in Patients With CirrHosis and Severe Acute-on-Chronic Liver Failure (ACLF): iNdications and outComEs
Management of ACLF is mainly supportive. The poor outcomes lead physicians to consider liver transplantation as an option, even if controversial. In sicker recipients, LT results in immediate survival, but poor medium-term survival rates in some studies. The scarcity of deceased donors obliges to maximize LT success. Alternative strategies, as living-donor LT, should be explored. LDLT has impressive results in Eastern centers, but it is restrained in Western countries, due to potential life-threatening complications in the donor.
Inclusion: 1. Male or female subject ≥18 years of age; Subjects with diagnosis of liver cirrhosis (based on clinical, laboratory, endoscopic, and ultrasonographic features or on histology); Subjects who have been hospitalized for acute decompensation of liver cirrhosis and referred to the transplant team:; Group 1: patients listed for liver transplantation with ACLF-2 or 3 at the time of listing or developing ACLF 2-3 while on the waiting list; Group 2: patients listed for liver transplantation with decompensated cirrhosis without ACLF-2 or 3 and poor liver function (MELD>20) at the time of listing; Group 3: patients having ACLF-2 or 3, are assessed for inclusion in the waiting list, but are finally not listed for liver transplantation; Patients (or trusted person, family member or close relation if the patient is unable to express consent) who have been informed and signed their informed consent Inclusion criteria.
Exclusion: -.